dipyridamole has been researched along with Acquired Autoimmune Hemolytic Anemia in 2 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Poldre, P | 1 |
Pruzanski, W | 1 |
Chiu, HM | 1 |
Dotten, DA | 1 |
Matloff, JM | 1 |
1 review available for dipyridamole and Acquired Autoimmune Hemolytic Anemia
Article | Year |
---|---|
Surgery for aortic valve disease.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Animals; Anticoagulants; Aortic Valve Insufficienc | 1971 |
1 other study available for dipyridamole and Acquired Autoimmune Hemolytic Anemia
Article | Year |
---|---|
Fulminant gangrene in transient cold agglutinemia associated with Escherichia coli infection.
Topics: Anemia, Hemolytic, Autoimmune; Cryoglobulins; Cytotoxicity, Immunologic; Dipyridamole; Endocarditis, | 1985 |